STOCK TITAN

AbbVie’s Azita Saleki exercises options on 13,481 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

AbbVie Inc. EVP and Chief Operations Officer Azita Saleki exercised options covering 13,481 shares at $61.36 per share on November 16, 2026; the reported option balance afterward was 23,935 shares. A separate common-stock row reports acquisition of 23,935 shares at $61.36 per share. The report also records 13,481 shares delivered or withheld for payment of exercise price or tax liability, at a weighted-average price of $298.55 across transactions from $298.55 to $298.64. No Rule 10b5-1 plan is reported. A profit sharing trust held 2,764 shares indirectly through the AbbVie Savings program as of November 16, 2026.

Insider SALEKI AZITA
Role EVP, CHIEF OPERATIONS OFFICER
Type Security Shares Price Value
Exercise Option (Right to Buy) F3 13,481 $0.00 $0.00
Exercise Common Stock, $0.01 par value 23,935 $61.36 $1.47M
Exercise Price or Tax Liability Common Stock, $0.01 par value F1 13,481 $298.55 $4.02M
Holding Common Stock, $0.01 par value F2 -- -- --
Holdings After Transaction: Option (Right to Buy) — 23,935 options (Direct); Common Stock, $0.01 par value — 208,248 shares (Direct); Common Stock, $0.01 par value — 2,764 shares (Indirect, Profit sharing trust)
Footnotes (3)
  1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.55 to $298.64, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2. Balance in AbbVie Savings program as of November 16, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
  3. F3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,957 on February 16, 2018, 15,956 on February 16, 2019, and 15,957 on February 16, 2020.
Options exercised 13,481 shares November 16, 2026
Option exercise price $61.36 per share Options exercised November 16, 2026
Option balance after transaction 23,935 shares Reported after the November 16, 2026 transaction
Common shares acquired 23,935 shares November 16, 2026; reported price was $61.36 per share
Shares delivered or withheld 13,481 shares For payment of exercise price or tax liability on November 16, 2026
Weighted-average price $298.55 per share Shares reported as sold in multiple transactions; prices ranged from $298.55 to $298.64
Indirect shares in profit sharing trust 2,764 shares AbbVie Savings program balance as of November 16, 2026
weighted average price financial
"The price reported is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 plan regulatory
"No Rule 10b5-1 plan is reported"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Rule 16b-3 regulatory
"transaction exempt from Section 16 under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
dividend reinvestment feature financial
"Balance includes shares acquired pursuant to a dividend reinvestment feature"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AbbVie options did Azita Saleki exercise, and at what price?

She exercised options covering 13,481 shares at $61.36 per share on November 16, 2026. The reported option balance afterward was 23,935 shares.

How many AbbVie common shares did Azita Saleki acquire and deliver or withhold?

The report records acquisition of 23,935 common shares at $61.36 per share and delivery or withholding of 13,481 shares for payment of exercise price or tax liability. The latter shares had a weighted-average price of $298.55, with transactions ranging from $298.55 to $298.64.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SALEKI AZITA

(Last)(First)(Middle)
1 N. WAUKEGAN ROAD

(Street)
NORTH CHICAGO ILLINOIS 60064

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, CHIEF OPERATIONS OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.01 par value11/16/2026M23,935A$61.36221,729D
Common Stock, $0.01 par value11/16/2026F13,481D$298.55(1)208,248D
Common Stock, $0.01 par value2,764(2)IProfit sharing trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (Right to Buy)$61.3611/16/2026M13,481 (3)02/15/2027Common Stock13,481$023,935D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.55 to $298.64, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. Balance in AbbVie Savings program as of November 16, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,957 on February 16, 2018, 15,956 on February 16, 2019, and 15,957 on February 16, 2020.
/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading